PROGENABIOME:
Progenabiome is a research genetic sequencing lab headquartered in Ventura, California. They are at the forefront of microbiome research with Next-Generation Sequencing (NGS) technology on-site and a mission to better understand, prevent, and treat diseases. Progenabiome CEO, Sabine Hazan, MD, has dedicated her life to patient care, clinical research, and humanitarian and social causes.
HELP COVID-19
Progenabiome is leading two FDA approved COVID-19 studies (“HELP COVID-19”) for immediate recruitment: one treatment protocol (PRG-044) and one prophylaxis protocol (PRG-042). Both will have oversight from the New England Independent Review Board (NEIRB), and additional trials are in the pipeline for review.
PRG-042 - A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19) https://clinicaltrials.gov/ct2/show/NCT04335084?term=progenabiome&draw=2&rank=37
PRG-044 - A Study of Quintuple Therapy to Treat COVID-19 Infection (HAZCpaC) https://clinicaltrials.gov/ct2/show/NCT04334512?term=progenabiome&draw=2&rank=38
SABINE HAZAN, MD, Founder & CEO
As a specialist in gastroenterology, internal medicine, and hepatology, Dr. Hazan has used her medical expertise in many regards over the last two decades. As the founder & CEO of Progenabiome, a genetic sequencing research laboratory, she leads 36+ studies investigating the role of the gut flora in various diseases (see current list here). Dr. Hazan is also the CEO of Ventura Clinical Trials, where she has 20+ years’ experience leading clinical trials for cutting-edge research on various medical issues. She is a top clinical investigator for multiple pharmaceutical companies.
The investigators will not be taking any fees or salary, as they are dedicated to helping treat patients in this pandemic. All monetary funding will be used to cover study expenses, including: medications, supplies, equipment, staff, testing, and operational costs.
As we look forward to being a part of the global solution in the treatment and recovery of COVID-19, the success of our studies is dependent on the collaboration of strong partners. If you would like to be a part of our research team and collaborate with us, please contact us.
Gather information / Participants
As we look forward to being a part of the global solution in the treatment and recovery of COVID-19, the success of our studies is dependent on the collaboration of strong partners. If you would like to be a part of our research team and collaborate with us, please contact us.
Interested in Participating?
The investigators will not be taking any fees or salary, as they are dedicated to helping treat patients in this pandemic. All monetary funding will be used to cover study expenses, including medications, supplies, equipment, staff, testing, and operational costs.
As we look forward to being a part of the global solution in the treatment and recovery of COVID-19, the success of our studies is dependent on the collaboration of strong partners. If you would like to be a part of our research team and collaborate with us, please contact us.
We are trying to develop a robust Clinical Trials workforce for COVID 19
Public—the broadest base of the pyramid consists of patients, families, and citizens who, in the final analysis, have the greatest stake in research results. This tier consists of engaged citizens who support the development of the CTE as a national resource or public good and who enroll in trials on a volunteer or basis.
Community practitioners—health professionals who participate in trials as part of their clinical practices, or at least help enroll their patients as participants. This group will include physicians, nurses, pharmacists, social workers, physical therapists, respiratory therapists, and other health professionals.
Implementers—individuals who devote specified portions of their professional efforts to serving as principal investigators or collaborating co-investigators, with primary responsibility for implementing clinical trials at a hospital or research site. This workforce group would include physician-scientists, nurse-investigators, clinical pharmacologists, research-oriented social workers, operations specialists, data managers, computer specialists, clinical research coordinators, and research site managers.
Investigators—leaders and designers of clinical trials and scientific experts who develop tools and innovative approaches for conducting trials. This group will include biostatisticians and informaticists, among others.
Methodologists—the apex of the pyramid consists of research-minded experts who explore the methodologies of conducting clinical trials and design the analysis portions of studies. This group of academicians will include clinical investigators, biostatisticians, epidemiologists, and health services researchers.